viewArix Bioscience PLC

Aura Biosciences reports positive clinical data on its eye cancer treatment therapy

Aura Biosciences Inc CEO Elisabet de los Pinos tells Proactive Investors the biotech has reported positive clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light- activated AU-011, its lead product candidate for the treatment of choroidal melanoma, a type of eye cancer.

Aura is a portfolio company of Arix Bioscience Plc (LSE: ARIX), a global health care and life sciences company.

De los Pinos says the company is privately held, however, a public offering would be considered towards the end of next year.

Quick facts: Arix Bioscience PLC

Price: 107.2 GBX

Market: LSE
Market Cap: £145.43 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...


Arix Bioscience Plc portfolio company Iterum Therapeutics updates on its...

Arix Bioscience Plc (LON:ARIX) portoflio company Iterum Therapeutics Plc (NASDAQ:ITRM) CEO Corey Fishman tells Proactive's Christine Corrado the Dublin, Ireland based clinical stage biopharma company is in Phase 3 with its antibiotic drug Sulopenem. Fishman says the company is developing...

on 10/31/2018

2 min read